- Home
- Protocols and Guidelines
- Cancer Protocol Templates
Cancer Protocol Templates
The CAP Cancer Reporting Protocols provide guidelines for collecting the essential data elements for complete reporting of malignant tumors and optimal patient care.
The CAP Biomarker Reporting Protocols are intended to provide reporting guidance for commonly ordered biomarkers and are not required for accreditation purposes.
Latest News and Resources
- Open all
- Close all
On December 14, 2022, the College of American Pathologists released updates to 15 CAP Cancer Protocols.
Highlights of content changes in this release include:
- NEW GYN Biomarker (not required for accreditation) replaces the retired Endometrium Biomarker protocol
- Updated Pediatric biopsy and resection protocols based on WHO 5th edition
- Updated Adrenal gland protocol based on WHO 5th edition
- Updated GIST biopsy, resection and biomarker protocols include content and explanatory notes
- Updated pTNM Classification remodeling
All changes are outlined in the Summary of Revisions [under Resources]
- Read the cancer protocol frequently asked questions.
- Download the definition of Synoptic Reporting With Examples.
- Visit the cancer protocol resources webpage to read about current issues with units of measurements.
- Integrate the Cancer Protocol & Biomarker Templates into your LIS workflow. Learn about our eCC (electronic Cancer Checklists) and eFRM (electronic Forms and Reporting Module)
- Download a compressed file containing all of current CAP cancer protocols.
- Download the current summary of revisions.
- Download the summary of required elements.
- Provide your feedback about the CAP cancer protocols to cprotoc@cap.org.
- June 2021 news release.
Current and previous cancer reporting and biomarker reporting protocols can be downloaded using the links in the table below.
On September 21, 2022, the College of American Pathologists released updates to 10 CAP Cancer Protocols. All changes are outlined in the Summary of Revisions with updates now available on www.cap.org.
New Cancer Reporting Protocol:
- Protocol for the Examination of Tumors of the Brain and Spinal Cord (v.1.0.0.0), which combines Integrated Diagnosis and Histological Assessment
Retired Cancer Reporting Protocol:
- Protocol for the Examination of Specimens from Patients with Tumors of the Central Nervous System (v.4.0.0.0), which includes separate case summaries for Integrated Diagnosis, Histological Assessment, and Biomarker Reporting
There are no changes to this release that affect accreditation dates.
Other key content changes include:
- The Expert Consultation question was made optional and an explanatory note was added in the Rhabdomyosarcoma and Ewing Sarcoma Biopsy and Resection templates
- Added Other (specify) and Cannot be determined (explain) answer options to the Margin Status question in the Breast Phyllodes template
- Updated the reporting note under Pathologic Stage Classification in the Lung Resection template
All changes are outlined in the Summary of Revisions [under Resources]
June 2022 CAP Cancer Protocol Update: Clarifications
- Anus and Appendix templates. While these updates include American Joint Committee on Cancer (AJCC) 9th version content, pathologists may continue to use the previous AJCC 8th version tumor stage classification system for cancer reporting until the updated content is required for use on January 1, 2023. The CAP released the updated cancer protocols ahead of the release of the 9th version staging system to allow organizations and laboratory information system (LIS) vendors sufficient time to make changes in their systems reflecting these updates.
- Protocol for Cutaneous Squamous Cell Carcinoma of the Head and Neck. This protocol is required for accreditation.
Previous Updates
On June 22, 2022, the College of American Pathologists released updates to 12 CAP Cancer Protocols. All changes are outlined in the Summary of Revisions.
New Cancer Reporting Protocol:
- Protocol for Cutaneous Squamous Cell Carcinoma of the Head and Neck
Changes affecting accreditation date:
- Anus and Appendix templates were updated to include AJCC 9th version content
- Added answers under Histologic Type to include Squamous Cell Carcinoma grading in the Major Salivary Gland template
- Deleted Tumor Modifier question and combined answer list with TNM Descriptors question for the Endometrium template
- Deprecated Hepatoblastoma from the Histologic Type answers in the Hepatocellular Carcinoma template
- Changed Distance from Invasive Carcinoma to Closest Margin from optional to core in the Lung template
- Updated the pN3a staging classification in the Breast Invasive template
Other key content changes include:
- Updated pN0 staging classification in the Breast Phyllodes template
- Changed the HER2 ISH question to conditional from optional, changed the Ki-67 question to core from optional, and deprecated the Multiparametric Gene Expression question in the Breast Biomarker template
All changes are outlined in the Summary of Revisions [under Resources]. Provide your feedback about the CAP cancer protocols to cprotoc@cap.org.
The College of American Pathologists March 2022 release updated 19 CAP Cancer Protocols.
Highlights of these content changes include:
- NEW Protocol – Phyllodes Tumor of the Breast
- All Pediatric Biopsy and Resection Protocols have an added question for Expert Consultation; for Wilms Tumor resection, this change affects the accreditation date
- Deprecated the Distance from Tumor to Vascular, Ureteral, and Soft Tissue Margin Questions for Wilms Tumor Resection: this change affects the accreditation date
- Lymphovascular Invasion was changed from an optional to a core element in the Breast Invasive Resection template which affects the accreditation date
- Clarified Number of Isolated Tumor Cells in the Uterine Sarcoma Resection template which affects the accreditation date
- Other minor content changes include explanatory note updates, corrections of typographical errors, and clarification of answer choices for peritoneal ascitic fluid
All changes are outlined in the Summary of Revisions [under Resources]
The College of American Pathologists November 2021 release updated 19 CAP Cancer Protocols. Highlights of these content changes include:
- Changed the name of the Lip and Oral Cavity to Oral Cavity to update scope of the protocol
- Added ITC reporting question and answer set to Regional Lymph Nodes in Uterus Sarcoma – will affect accreditation date
- Changed nested Margin questions from Conditional to Required and Remodeled Preexisting pleomorphic adenoma component question in Head and Neck Protocols
- Updated Not Applicable statement to state "invasive melanoma" vs "invasive carcinoma" and cover page to qualify use for Invasive Melanoma Excision
- Added a new, repeating section for other user entered biomarkers in Quantitative IHC Biomarker Reporting
- Updated instructional and explanatory notes
- Reformatted Questions and Answers, and reporting order of elements
There are no new or retired protocols in this release. Additionally, there were 13 protocols that underwent technical changes only to their corresponding CAP eCC template. Although these protocols did not have any content changes, they received new version numbers to reconcile our database.
All changes are outlined in the Summary of Revisions [under Resources]
Cancer Reporting and Biomarker Reporting Protocols
2013-2018 Previous Versions Are Available Upon Request
Breast
Breast DCIS, Resection | Previous Version 2020 (v4.3.0.2) 2019 (v4.3.0.1) 2019 (v4.3.0.0) 2019 (v4.2.0.0) |
|
Breast DCIS, Biopsy | Current Version PDF (v1.0.1.0) Word (v1.0.1.0) June 2021 |
Previous Version 2020 (v1.0.0.1) 2019 (v1.0.0.0) |
Breast Phyllodes Tumor | Current Version PDF (v1.1.0.1) Word (v1.1.0.1) September 2022 |
Previous Version 2022 (v1.1.0.0) 2022 (v.1.0.0.0) |
Breast Invasive, Resection | Current Version PDF (v4.8.0.0) Word (v4.8.0.0) December 2022 |
Previous Version 2022 (v4.7.0.1) 2022 (v4.7.0.0) 2022 (v4.6.0.0) 2021 (v4.5.0.1) 2021 (v4.5.0.0) 2020 (v4.4.0.0) 2019 (v4.3.0.1) |
Breast Invasive, Biopsy | Current Version PDF (v1.1.1.2) Word (v1.1.1.2) September 2022 |
Previous Version 2021 (v1.1.1.1) 2021 (v1.1.1.0) 2020 (v1.1.0.0) 2019 (v1.0.0.1) 2019 (v1.0.0.0) |
Breast Biomarker Reporting | Current Version PDF (v1.5.0.0) Word (v1.5.0.0) June 2022 |
Previous Version 2021 (v1.4.1.1) 2021 (v1.4.1.0) 2020 (v1.4.0.0) 2019 (v1.3.0.0) |
Central Nervous System
Endocrine
Adrenal Gland | Current Version PDF (v4.3.0.0) Word (v4.3.0.0) December 2022 |
Previous Version 2021 (v4.2.1.0) 2021 (v4.2.0.0) 2020 (v4.1.0.0) 2019 (v4.0.2.0) |
Appendix NET | Current Version PDF (v4.1.0.0) Word (v4.1.0.0) June 2021 |
Previous Version 2020 (v4.0.0.2) |
Colon NET | Current Version PDF (v4.1.0.0) Word (v4.1.0.0) June 2021 |
Previous Version 2020 (v4.0.0.2) |
Duodenum and Ampulla NET | Current Version PDF (v1.1.0.0) Word (v1.1.0.0) June 2021 |
Previous Version 2020 (v1.0.0.2) |
Jejunum and Ileum NET | Current Version PDF (v1.1.0.0) Word (v1.1.0.0) June 2021 |
Previous Version 2020 (v1.0.0.1) |
Pancreas (Endocrine) | Current Version PDF (v4.1.0.0) Word (v4.1.0.0) June 2021 |
Previous Version 2020 (v4.0.0.2) |
Stomach NET | Current Version PDF (v4.1.0.0) Word (v4.1.0.0) June 2021 |
Previous Version 2020 (v4.0.0.2) |
Thyroid | Current Version PDF (v4.3.0.0) Word (v4.3.0.0) June 2021 |
Previous Version 2020 (v4.2.0.0) 2019 (v4.1.0.0) |
Thyroid Biomarker Reporting | Current Version PDF (v1.0.0.1) Word (v1.0.0.1) June 2016 |
Previous Version 2015 (v1.0.0.0) |
Gastrointestinal
Ampulla of Vater | Current Version PDF (v4.2.0.1) Word (v4.2.0.1) November 2021 |
Previous Version 2021 (v4.2.0.0) 2020 (v4.1.0.0) |
Anus, Excision | Current Version PDF (v4.2.0.0) Word (v4.2.0.0) June 2021 |
Previous Version 2020 (v4.1.0.1) 2020 (v4.1.0.0) |
Anus, Resection | Current Version PDF (v5.0.0.0) Word (v5.0.0.0) June 2022 |
Previous Version 2021 (v4.2.0.1) 2021 (v4.2.0.0) 2020 (v4.1.0.0) |
Appendix | Current Version PDF (v5.1.0.0) Word (v5.1.0.0) December 2022 |
Previous Version 2022 (v5.0.0.0) 2021 (v4.2.0.0) 2020 (v4.1.0.0) |
Colon and Rectum, Biopsy | Current Version PDF (v4.2.0.1) Word (v4.2.0.1) November 2021 |
Previous Version 2021 (v4.2.0.0) 2020 (v4.1.0.0) |
Colon and Rectum, Resection | Current Version PDF (v4.2.0.2) Word (v4.2.0.2) June 2022 |
Previous Version 2021 (v4.2.0.1) 2021 (v4.2.0.0) 2020 (v4.1.0.0) |
Colon and Rectum Biomarker Reporting | Current Version PDF (v1.3.0.0) Word (v1.3.0.0) June 2021 |
Previous Version 2014 (v1.2.0.1) |
Distal Extrahepatic Bile Ducts | Current Version PDF (v4.2.0.0) Word (v4.2.0.0) June 2021 |
Previous Version 2020 (v4.1.0.0) |
Esophagus | Current Version PDF (v4.2.0.1) Word (v4.2.0.1) June 2022 |
Previous Version 2021 (v4.2.0.0) 2020 (v4.1.0.0) |
Gallbladder | Current Version PDF (v4.2.0.0) Word (v4.2.0.0) June 2021 |
Previous Version 2020 (v4.1.0.0) |
GIST, Biopsy | Current Version PDF (v4.3.0.0) Word (v4.3.0.0) December 2022 |
Previous Version 2021 (v4.2.0.0) 2020 (v4.1.0.0) |
GIST, Resection | Current Version PDF (v4.3.0.0) Word (v4.3.0.0) December 2022 |
Previous Version 2021 (v4.2.0.0) 2020 (v4.1.0.0) |
GIST Biomarker Reporting | Current Version PDF (v1.1.0.0) Word (v1.1.0.0) December 2022 |
Previous Version 2020 (v1.0.0.2) 2015 (v1.0.0.1) 2014 (v1.0.0.0) |
Hepatocellular Carcinoma | Current Version PDF (v4.3.0.0) Word (v4.3.0.0) June 2022 |
Previous Version 2021 (v4.2.0.0) 2020 (v4.1.0.0) |
Intrahepatic Bile Ducts | Current Version PDF (v4.2.0.0) Word(v4.2.0.0) June 2021 |
Previous Version 2020 (v4.1.0.0) |
Pancreas (Exocrine) | Current Version PDF (v4.2.0.2) Word (v4.2.0.2) November 2021 |
Previous Version 2021 (v4.2.0.1) 2021 (v4.2.0.0) 2020 (v4.1.0.0) |
Perihilar Bile Ducts | Current Version PDF (v4.2.0.0) Word (v4.2.0.0) June 2021 |
Previous Version 2020 (v4.1.0.0) |
Small Intestine | Current Version PDF (v4.2.0.0) Word (v4.2.0.0) June 2021 |
Previous Version 2020 (v4.1.0.0) |
Stomach | Current Version PDF (v4.3.0.0) Word (v4.3.0.0) December 2022 |
Previous Version 2022 (v4.2.1.1) 2021 (v4.2.1.0) 2021 (v4.2.0.0) 2020 (v4.1.0.0) |
Gastric HER2 Biomarker Reporting | Current Version PDF (v1.0.0.1) Word (v1.0.0.1) June 2017 |
Previous Version 2014 (v1.0.0.0) |
Genitourinary
Kidney, Biopsy | Current Version PDF (v4.1.0.0) Word (v4.1.0.0) June 2021 |
Previous Version 2020 (v4.0.2.0) |
Kidney, Resection | Current Version PDF (v4.1.0.0) Word (v4.1.0.0) June 2021 |
Previous Version 2020 (v4.0.2.0) |
Penis | Current Version PDF (v4.1.0.0) Word (v4.1.0.0) June 2021 |
Previous Version 2017 (v4.0.1.0) |
Prostate Needle Biopsy Case Level | Current Version PDF (1.0.0.1) Word (1.0.0.1) November 2021 | Previous Version 2021 (1.0.0.0) |
Prostate Needle Biopsy Specimen Level | Current Version PDF (1.0.0.1) Word(1.0.0.1) November 2021 | Previous Version 2021 (1.0.0.0) |
Prostate, Resection | Current Version PDF (v4.2.0.1) Word (v4.2.0.1) November 2021 |
Previous Version 2021 (v4.2.0.0) 2020(v4.1.0.1) 2019 (v4.0.4.1) 2019 (v4.0.4.0) |
Prostate TURP | Current Version PDF (v4.1.0.0) Word (v4.1.0.0) June 2021 |
Previous Version 2020 (v4.0.5.0) 2019 (v4.0.4.1) |
Testis Radical Orchiectomy | Current Version PDF (v4.1.0.1) Word(v4.1.0.1) November 2021 |
Previous Version 2021 (v4.1.0.0) 2019 (v4.0.1.2) |
Testis Lymphadenectomy | Current Version PDF (v4.1.0.1) Word (v4.1.0.1) November 2021 |
Previous Version 2021 (v4.1.0.0) 2019 (v4.0.1.1) |
Ureter, Renal Pelvis, Biopsy | Current Version PDF (v2.2.0.0) Word (v2.2.0.0) June 2021 |
Previous Version 2019 (v2.1.0.0) |
Ureter, Renal Pelvis, Resection | Current Version PDF (v2.2.0.0) Word (v2.2.0.0) June 2021 |
Previous Version 2019 (v2.1.0.0) |
Urethra, Biopsy | Current Version PDF (v4.1.0.0) Word (v4.1.0.0) June 2021 |
Previous Version 2019 (v4.0.2.0) |
Urethra, Resection | Current Version PDF (v4.1.0.0) Word (v4.1.0.0) June 2021 |
Previous Version 2020 (v4.0.3.0) 2019 (v4.0.2.0) |
Urinary Bladder, Resection | Current Version PDF (v4.1.0.0) Word (v4.1.0.0) June 2021 |
Previous Version 2020 (v4.0.2.0) 2019 (v4.0.1.1) |
Urinary Bladder, Biopsy | Current Version PDF (v4.1.0.0) Word (v4.1.0.0) June 2021 |
Previous Version 2020 (v4.0.2.0) 2019 (v4.0.1.1) |
Gynecologic
Endometrium Uterus | Current Version PDF (v4.4.0.0) Word (v4.4.0.0) December 2022 |
Previous Version 2022 (v4.3.0.0) 2022 (v4.2.0.2) 2021 (v4.2.0.1) 2021 (v4.2.0.0) 2020 (v4.1.0.2) 2019 (v4.1.0.1) |
Endometrium Biomarker Reporting *RETIRED* | Last Version PDF (v1.2.0.1) September 2019 |
|
Gynecologic, Biomarkers *NEW* | Current Version PDF (v1.0.0.0) Word (v1.0.0.0) December 2022 |
|
Ovary, Fallopian Tube, or Peritoneum | Current Version PDF(v1.3.0.2) Word (v1.3.0.2) March 2022 |
Previous Version 2021 (v1.3.0.1) 2021 (v1.3.0.0) 2020 (v1.1.1.0) |
Trophoblastic Tumors | Current Version PDF (v4.1.0.1) Word (v4.1.0.1) November 2021 |
Previous Version 2021 (v4.1.0.0) 2017 (v4.0.0.0) |
Uterine Cervix, Excision | Current Version PDF (v4.4.1.0) Word (v4.4.1.0) June 2021 |
Previous Version 2020 (v4.4.0.0) 2020 (v4.3.0.0) 2019 (v4.2.0.0) |
Uterine Cervix, Resection | Current Version PDF (v5.0.1.3) Word (v5.0.1.3) March 2022 |
Previous Version 2021(v5.0.1.2) 2021 (v5.0.1.1) 2021 (v5.0.1.0) 2020 (v5.0.0.0) 2020 (v4.3.0.0) |
Uterine Sarcoma | Current Version PDF (v4.4.0.0) Word (v4.4.0.0) March 2022 |
Previous Version 2021 (v4.3.0.0) 2021 (v4.2.0.0) 2018 (v4.1.0.0) |
Vagina, Biopsy | Current Version PDF (v4.3.0.0) Word (v4.3.0.0) June 2021 |
Previous Version 2019 (v4.2.0.0) |
Vagina, Resection | Current Version PDF (v4.3.0.1) Word(v4.3.0.1) November 2021 |
Previous Version 2021 (v4.3.0.0) 2020 (v4.2.0.1) 2019 (v4.2.0.0) |
Vulva | Current Version PDF (v4.2.0.2) Word (v4.2.0.2) November 2021 |
Previous Version 2021 (v4.2.0.1) 2021 (v4.2.0.0) 2020 (v4.1.0.1) |
Head and Neck
Larynx | Current Version PDF (v4.1.1.0) Word (v4.1.1.0) November 2021 |
Previous Version 2021 (v4.1.0.0) 2017 (v4.0.0.1) |
Oral Cavity | Current Version PDF (v4.1.1.0) Word (v4.1.1.0) November 2021 |
Previous Version 2021 (v4.1.0.1) 2021 (v4.1.0.0) 2017 (v4.0.0.1) |
Major Salivary Glands | Current Version PDF (v4.2.0.0) Word (v4.2.0.0) June 2022 |
Previous Version 2021 (v4.1.1.0) 2021 (v4.1.0.0) 2017 (v4.0.0.1) |
Nasal Cavity and Paranasal Sinuses | Current Version PDF (v4.1.1.0) Word (v4.1.1.0) November 2021 |
Previous Version 2021 (v4.1.0.0) 2017 (v4.0.0.1) |
Pharynx | Current Version PDF (v4.1.1.0) Word (v4.1.1.0) November 2021 |
Previous Version 2021 (v4.1.0.0) 2019 (v4.0.0.2) |
Head and Neck Biomarker Reporting | Current Version PDF (v2.0.0.1) Word (v2.0.0.1) November 2021 |
Previous Version 2021 (v2.0.0.0) 2017 (v1.0.0.0) |
Squamous Cell Carcinoma | Current Version PDF (v1.0.0.1) Word (v1.0.0.1) September 2022 | Previous Version 2022 (v1.0.0.0) |
Hematologic
Bone Marrow | Current Version PDF (v4.0.0.0) Word (v4.0.0.0) February 2019 |
Previous Version 2018 (v3.1.0.0) 2017 (v3.0.1.2) 2012 (v3.0.1.1) |
Hodgkin Lymphoma | Current Version PDF (v3.1.0.1) Word (v3.1.0.1) October 2013 |
Previous Version 2013 (v3.1.0.0) |
Non-Hodgkin Lymphoma | Current Version PDF (v3.2.0.1) Word (v3.2.0.1) October 2013 |
Previous Version 2013 (v3.2.0.0) |
Plasma Cell Neoplasms | Current Version PDF (v1.0.0.2) Word (v1.0.0.2) January 2015 |
Previous Version 2015 (v1.0.0.1) 2015 (v1.0.0.0) |
Ophthalmic
Pediatric
Ewing, Resection | Current Version PDF (v4.1.1.1) Word (v4.1.1.1) September 2022 |
Previous Version 2022 (v4.1.1.0) 2021 (v4.1.0.0) 2019 (v4.0.0.0) |
Ewing, Biopsy | Current Version PDF (v4.1.1.1) Word (v4.1.1.1) September 2022 |
Previous Version 2022 (v4.1.1.0) 2021 (v4.1.0.0) 2019 (v4.0.0.0) |
Germ Cell Tumor, Resection | Current Version PDF (v4.1.1.0) Word (v4.1.1.0) March 2022 |
Previous Version 2021 (v4.1.0.0) 2019 (v4.0.0.0) |
Germ Cell Tumor, Biopsy | Current Version PDF (v4.1.1.0) Word (v4.1.1.0) March 2022 |
Previous Version 2021 (v4.1.0.0) 2019 (v4.0.0.0) |
Hepatoblastoma, Resection | Current Version PDF (v4.1.0.0) Word (v4.1.0.0) December 2022 |
Previous Version 2022 (v4.0.2.0) 2021 (v4.0.1.0) 2019 (v4.0.0.0) |
Hepatoblastoma, Biopsy | Current Version PDF (v4.1.0.0) Word (v4.1.0.0) December 2022 |
Previous Version 2022 (v4.0.1.0) 2021 (v4.0.0.1) 2019 (v4.0.0.0) |
Neuroblastoma, Resection | Current Version PDF (v4.2.0.0) Word (v4.2.0.0) December 2022 |
Previous Version 2022 (v4.1.1.0) 2021 (v4.1.0.0) 2019 (v4.0.0.0) |
Neuroblastoma, Biopsy | Current Version PDF (v4.2.0.0) Word (v4.2.0.0) December 2022 |
Previous Version 2022 (v4.1.1.0) 2021 (v4.1.0.0) 2019 (v4.0.0.0) |
Rhabdomyosarcoma, Resection | Current Version PDF (v4.1.1.1) Word (v4.1.1.1) September 2022 |
Previous Version 2022 (v4.1.1.0) 2021 (v4.1.0.0) 2019 (v4.0.0.0) |
Rhabdomyosarcoma, Biopsy | Current Version PDF (v4.1.1.1) Word (v4.1.1.1) September 2022 |
Previous Version 2022 (v4.1.1.0) 2021 (v4.1.0.0) 2019 (v4.0.0.0) |
Wilms, Resection | Current Version PDF (v4.3.0.0) Word (v4.3.0.0) December 2022 |
Previous Version 2022 (v4.2.0.0) 2021 (v4.1.0.0) 2019 (v4.0.0.0) |
Wilms, Biopsy | Current Version PDF (v4.1.0.0) Word (v4.1.0.0) December 2022 |
Previous Version 2022 (v4.0.1.0) 2021 (v4.0.0.1) 2019 (v4.0.0.0) |
Skin
Skin, Melanoma, Biopsy | Current Version PDF (v4.3.1.0) Word (v4.3.1.0) March 2022 |
Previous Version 2021 (v4.3.0.1) 2021 (v4.3.0.0) 2020 (v4.2.0.0) 2020 (v4.1.1.0) 2019 (v4.1.0.0) |
Skin, Melanoma, Excision | Current Version PDF (v4.3.0.2) Word (v4.3.0.2) November 2021 |
Previous Version 2021 (v4.3.0.1) 2021 (v4.3.0.0) 2020 (v4.2.0.0) 2020 (v4.1.0.0) |
Melanoma Biomarker Reporting | Current Version PDF (v1.0.0.2) Word (v1.0.0.2) July 2015 |
Previous Version 2015 (v1.0.0.1) 2015 (v1.0.0.0) |
Merkel Cell Carcinoma | Current Version PDF (v4.1.0.0) Word (v4.1.0.0) June 2021 |
Previous Version 2017 (v4.0.0.1) |
Thorax
Lung, Resection | Current Version PDF (v4.3.0.1) Word (v4.3.0.1) September 2022 |
Previous Version 2022 (v4.3.0.0) 2021 (v4.2.0.1) 2021 (v4.2.0.0) 2020 (v4.1.0.1) 2019 (v4.1.0.0) |
Lung Biomarker Reporting | Current Version PDF (v2.0.1.0) Word (v2.0.1.0) November 2021 |
Previous Version 2021 (v2.0.0.0) 2016 (v1.3.0.2) |
Pleural Mesothelioma | Current Version PDF (v4.1.0.0) Word (v4.1.0.0) June 2021 |
Previous Version 2017 (v4.0.0.1) |
Thymus | Current Version PDF (v4.1.0.0) Word (v4.1.0.0) June 2021 |
Previous Version 2017 (v4.0.0.1) |
Bone and Soft Tissue
Bone, Biopsy | Current Version PDF (v4.1.0.1) Word (v4.1.0.1) November 2021 |
Previous Version 2021 (v4.1.0.0) 2020 (v4.0.1.0) |
Bone, Resection | Current Version PDF (v4.1.1.0) Word (v4.1.1.0) July 2021 |
Previous Version 2021 (v4.1.0.0) 2020 (v4.0.1.0) |
Soft Tissue, Biopsy | Current Version PDF (v4.1.0.0) Word (v4.1.0.0) June 2021 |
Previous Version 2020 (v4.0.2.0) 2019 (v4.0.1.1) |
Soft Tissue, Resection | Current Version PDF (v4.1.0.0) Word (v4.1.0.0) June 2021 |
Previous Version 2020 (v4.0.2.0) 2019 (v4.0.1.1) |
General
DNA Mismatch Repair Biomarker Reporting | Current Version PDF (v1.0.0.2) Word (v1.0.0.2) June 2021 |
Previous Version 2018 (v1.0.0.0) |
Generic Template, Biopsy | Current Version PDF (v1.0.1.0) Word (v1.0.1.0) June 2021 |
Previous Version 2019 (v1.0.0.0) |
Generic Template, Resection | Current Version PDF (v1.1.0.0) Word (v1.1.0.0) June 2021 |
Previous Version 2019 (v1.0.0.0) |
General IHC Quantitative Biomarkers | Current Version PDF (1.1.0.0) Word (1.1.0.0) November 2021 | Previous Version 2021 (1.0.0.0) |
CAP Cancer Protocol Usage Limitations and Copyright
© 2022 College of American Pathologists (CAP). All rights reserved.
The College of American Pathologists (CAP) does not permit reproduction of any substantial portion of these protocols without its written authorization. The CAP hereby authorizes use of these protocols by physicians and other health care providers in reporting on surgical specimens, in teaching, and in carrying out medical research for nonprofit purposes. This authorization does not extend to reproduction or other use of any substantial portion of these protocols for commercial purposes without the written consent of the CAP.
The CAP also authorizes physicians and other health care practitioners to make modified versions of the Protocols solely for their individual use in reporting on surgical specimens for individual patients, teaching, and carrying out medical research for non-profit purposes.
The CAP further authorizes the following uses by physicians and other health care practitioners, in reporting on surgical specimens for individual patients, in teaching, and in carrying out medical research for non-profit purposes: (1) Dictation from the original or modified protocols for the purposes of creating a text-based patient record on paper, or in a word processing document; (2) Copying from the original or modified protocols into a text-based patient record on paper, or in a word processing document; (3) The use of a computerized system for items (1) and (2), provided that the protocol data is stored intact as a single text-based document, and is not stored as multiple discrete data fields.
Other than uses (1), (2), and (3) above, the CAP does not authorize any use of the Protocols in electronic medical records systems, pathology informatics systems, cancer registry computer systems, computerized databases, mappings between coding works, or any computerized system without a written license from the CAP.
Any public dissemination of the original or modified protocols is prohibited without a written license from the CAP.
The Protocols include tumor staging data used with permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this information is the AJCC Cancer Staging System (2020).
The CAP developed these protocols as an educational tool to assist pathologists in the useful reporting of relevant information. It did not issue the protocols for use in litigation, reimbursement, or other contexts. Nevertheless, the CAP recognizes that the protocols might be used by hospitals, attorneys, payers, and others. Indeed, effective January 1, 2004, the Commission on Cancer of the American College of Surgeons mandated the use of the required data elements of the protocols as part of its Cancer Program Standards for Approved Cancer Programs. Therefore, it becomes even more important for pathologists to familiarize themselves with these documents. At the same time, the CAP cautions that use of the protocols other than for their intended educational purpose may involve additional considerations that are beyond the scope of this document.
The inclusion of a product name or service in a CAP publication should not be construed as an endorsement of such product or service, nor is failure to include the name of a product or service to be construed as disapproval.
Contact Information
Please direct questions or comments regarding CAP Cancer Protocols to cancerprotocols@cap.org.